"L-carnitine danger" is among the most frequent searches for this supplement. The question is legitimate: it's a molecule taken daily, often for months, by athletes or people seeking to lose weight. Studies allow us to answer this precisely.
This guide compiles what they measure: the frequency of adverse effects in trials, the dose studied safely in prolonged use, the origin of the fishy odor, the question of TMAO and the heart, liver, kidneys and blood pressure, then interactions and situations where medical advice is necessary.
Tolerance : in 17 cardiology trials, 5.4% adverse effects under carnitine versus 5.8% under placebo, mainly digestive, with dry mouth. Nausea and diarrhea depend on the dose. The reference assessment places the observed safety level at 2,000 mg per day in prolonged use. A fishy body odor is possible at high doses and disappears upon cessation.
Heart, liver, blood pressure : carnitine multiplies blood TMAO, a molecule studied as a cardiovascular marker, without modifying inflammation markers in healthy older women; a trial in high cardiovascular risk individuals warrants caution, while trials after heart attack point rather toward a benefit. Liver enzymes tend to decrease rather than increase, and blood pressure does not change. Medical advice under anticoagulant antivitamin K therapy, thyroid treatment or valproate, in dialysis, during pregnancy and in case of cardiovascular disease.
- Adverse effects measured in trials
- What dose is safe
- The fishy odor: where it comes from
- The heart: TMAO, cardiology trials and blood pressure
- Liver, kidneys and dialysis
- Thyroid and anticoagulants: interactions
- Pregnancy, epilepsy, D,L form: other questions
- Who should seek medical advice
- Frequently asked questions
Adverse effects measured in trials
The largest review comes from trials conducted in patients, who often receive higher doses than athletes, over months. A 2017 meta-analysis brought together 17 randomized trials in 1,625 heart failure patients.
Patients received 1.5 to 6 g of L-carnitine per day, for 7 days to 3 years, in addition to their treatment. Adverse effects occurred in 5.4% of patients on carnitine and 5.8% of control patients, a non-significant difference; the most frequent were dry mouth and digestive disorders, and no patient discontinued due to them. Carnitine also improved the heart's ejection fraction by 4.1 points and reduced BNP, a marker of heart failure, with no difference in mortality.
Song X, Qu H, Yang Z, Rong J, Cai W, Zhou H. Biomed Res Int 2017;2017:6274854. DOI: 10.1155/2017/6274854
In healthy athletes, a crossover trial gave 3 g of L-carnitine L-tartrate per day for three weeks to ten active men: no variable from a complete blood panel, liver and kidney markers, electrolytes, cell count, differed from placebo. Over six months at 2 g per day, in 157 adults with metabolic syndrome, digestive disorders, fish odor and seizures were monitored, with no notable difference between groups.
Dose matters. The regional pharmacovigilance center in Nice reminds that diarrhea, dose-dependent, is the main adverse effect of L-carnitine; in a trial at 4 g per day in obese women, five participants in the carnitine group discontinued due to nausea or diarrhea.
| Effect | What is observed | Source |
|---|---|---|
| Nausea, diarrhea | Dose-dependent; discontinuations at 4 g per day | 2000 trial, pharmacovigilance 2011 |
| Dry mouth | Among the most frequent in heart failure patients | 2017 meta-analysis |
| Skin rash | 4 patients out of 43 versus 2 out of 43 in one trial | 2017 meta-analysis |
| Fish odor body odor | Published cases, disappearance upon discontinuation | Pharmacovigilance 2011 |
| Blood panel | No abnormalities at 3 g of L-tartrate per day | 2001 trial |
What dose is safe
In 2006, a risk assessment reviewed published trials and set the observed safety level at 2,000 mg of L-carnitine per day with prolonged use: below this, safety evidence is considered solid. Higher doses have been tested without notable adverse effects, but over periods too short to conclude on the long term.
Other doses were well tolerated in medical contexts: 1.5 to 6 g per day for up to three years in heart failure patients, 2 to 4 g per day for six months in a thyroid trial. Two capsules of our L-carnitine provide 1,500 mg of L-carnitine L-tartrate, or approximately 1,000 mg of L-carnitine, half the observed safety level; this is the L-tartrate dose taken for 24 weeks by women aged 65 to 70 in the trial detailed below.
Fish odor: where it comes from
In the intestine, bacteria transform part of the carnitine and choline into trimethylamine, a molecule with a fish odor. The liver normally oxidizes it into TMAO, odorless, eliminated in the urine. When this oxidation is overwhelmed or deficient, trimethylamine passes into the breath, sweat, and urine: this is fish odor syndrome, or trimethylaminuria.
With carnitine, this syndrome was described by the regional pharmacovigilance center in Nice in a treated patient, with disappearance after discontinuation; the authors link it to excessive intake or a saturated elimination pathway. In practice, an unusual odor leads to dose reduction or discontinuation, and people with known trimethylaminuria refrain from use.
The heart: TMAO, cardiology trials, and blood pressure
The question stems from a 2013 study published in Nature Medicine. In mice, carnitine accelerated atherosclerosis, but not when intestinal bacteria were suppressed: it was TMAO, formed by the microbiota then the liver, that seemed to be responsible. In humans, meat eaters produced more TMAO than vegetarians and vegans, and in 2,595 cardiology patients followed, blood carnitine was associated with event risk only in the presence of elevated TMAO. A 2019 study clarified the mechanism: after a dose of labeled carnitine, omnivores produced more than 20 times more TMAO than vegans and vegetarians, and supplementation for two months or more made this bacterial pathway more active.
Healthy women aged 65 to 70 took 1,500 mg of L-carnitine L-tartrate per day or placebo for 24 weeks. Plasma TMAO increased tenfold, to 33.6 µmol/L versus 2.9 under placebo, with no change in CRP, interleukin 6, TNF-alpha, vascular adhesion molecules, or blood lipids. Four months after discontinuation, TMAO had returned to the placebo group level, and remained there at twelve months.
Samulak JJ, et al. Ann Nutr Metab 2019;74(1):11-17. DOI: 10.1159/000495037 ; Nutrients 2019;11(6):1322. DOI: 10.3390/nu11061322
In high-risk individuals, the signal is less reassuring. In a six-month randomized trial in 157 adults with metabolic syndrome and carotid plaques, 2 g of L-carnitine per day did not modify total plaque volume, the primary endpoint, but carotid narrowing progressed more than with placebo, by 9.3%, with a more marked increase in total cholesterol and LDL. The authors consider this signal concerning and call for caution in this population.
Conversely, after a heart attack, a meta-analysis of 13 trials and 3,629 patients associated carnitine with 27% lower total mortality, at the borderline of significance, with 65% fewer ventricular arrhythmias and 40% less angina, with no effect on heart failure or reinfarction. And in heart failure patients, the meta-analysis of 17 trials found improved cardiac function.
At present, TMAO rises in a real and reversible manner, and what this increase means for the heart is not settled. In a healthy person, measured markers do not change. In a person with cardiovascular disease or at high risk, the decision is made with the cardiologist.
A meta-analysis of 22 trials and 1,412 adults, published in 2024, found no significant effect of L-carnitine on blood pressure: 1.22 mmHg lower for systolic and 0.50 mmHg lower for diastolic, two non-significant differences. L-carnitine does not raise blood pressure.
The liver, kidneys, and dialysis
Eighteen randomized trials, 1,161 participants, doses from 500 to 4,000 mg per day: L-carnitine lowered liver enzymes, ALT by 8.65 IU/L, AST by 8.52 IU/L, and GGT by 8.80 IU/L. The effect was more pronounced at 2 g per day and above, beyond 12 weeks, and in people with liver disease. The authors consider the level of evidence moderate for ALT and AST.
Pirmadah F, Ramezani-Jolfaie N, Mohammadi M, et al. Eur J Nutr 2020;59(5):1767-1783. DOI: 10.1007/s00394-019-02068-4
Trials report no liver toxicity, and at 3 g of L-carnitine L-tartrate per day, no liver or kidney markers changed in healthy men. In dialysis patients, who lose carnitine through the dialyzer, L-carnitine is actually a treatment: a meta-analysis of 49 trials and 1,734 hemodialysis patients showed a reduction in LDL-cholesterol and CRP, with no effect on hemoglobin or albumin, and no reported adverse effects. This is a prescribed and monitored use: in case of kidney disease, carnitine should not be taken without the nephrologist's advice.
The same logic applies to valproate, an antiepileptic: L-carnitine is used in hospital against its toxicity. A review of published cases of valproate poisoning treated with intravenous carnitine reports recovery in all patients and no adverse effects in the safety data of 674 patients. This use remains medical: with valproate, carnitine should be discussed with the neurologist.
Thyroid and anticoagulants: the interactions
Fifty women receiving levothyroxine at suppressive dose, thus in excess thyroid hormones, took 2 or 4 g of L-carnitine per day or placebo for six months. Carnitine reversed or prevented hyperthyroidism symptoms, with equal efficacy at both doses. The mechanism: it slows the entry of thyroid hormones into cell nuclei, making it a peripheral antagonist of their action.
Benvenga S, Ruggeri RM, Russo A, Lapa D, Campenni A, Trimarchi F. J Clin Endocrinol Metab 2001;86(8):3579-3594. DOI: 10.1210/jcem.86.8.7747
For a person treated for hypothyroidism, this mechanism raises a theoretical question: carnitine could reduce the effect of their treatment. The available trial is rather reassuring: in 60 hypothyroid patients on levothyroxine, 990 mg of L-carnitine twice daily for 12 weeks reduced mental fatigue. Caution remains warranted: the doctor can check TSH after introduction.
Two published cases, in 1993 and 2004, describe an enhancement of the effect of acenocoumarol, an antivitamin K anticoagulant, after the addition of L-carnitine, in one woman and one man with a heart valve. With antivitamin K, carnitine is added only with the doctor's approval and INR monitoring, both at initiation and at discontinuation.
Pregnancy, epilepsy, D,L form: other questions
Pregnancy. Blood carnitine naturally decreases during pregnancy. A small trial gave 500 mg of L-carnitine daily, in L-tartrate form, to 13 pregnant women from week 13 to term, versus 13 receiving placebo: supplementation prevented this decline. Safety was not detailed in the study abstract and large trials exclude pregnant or nursing women: during pregnancy and breastfeeding, carnitine should only be taken on medical advice.
Epilepsy. We found no published case in PubMed of an epileptic seizure triggered by carnitine in humans. However, trials exclude epileptic individuals as a precaution, and in the six-month trial at 2 g daily, where seizures were monitored, none were observed.
D,L form. Only the L form is natural and used in supplements. A letter published in The Lancet in 1981 described a syndrome of muscle weakness similar to myasthenia with D,L-carnitine mixture, not with L-carnitine. The form is listed on the label.
Who should seek medical advice
| Situation | Why | Source |
|---|---|---|
| Anticoagulant antivitamin K | Effect of acenocoumarol strengthened in two cases; INR monitoring | Cases from 1993 and 2004 |
| Thyroid treatment | Inhibits the action of thyroid hormones in cells | Trials from 2001 and 2016 |
| Valproate, epilepsy | Medical use against valproate toxicity; trials excluded | 2010 review, 2022 trial |
| Dialysis, kidney disease | Medical use prescribed and monitored | 2014 meta-analysis |
| Cardiovascular disease, metabolic syndrome | Increased TMAO; signal for carotid narrowing | Trials from 2019 and 2022 |
| Pregnancy, breastfeeding | Insufficient data | 2009 trial |
| Trimethylaminuria | Carnitine is a source of trimethylamine | 1999 review |
Outside these situations, in healthy adults, trials describe tolerance close to placebo up to 2 g of L-carnitine daily. For benefits and food sources, our L-carnitine guide provides the details.
1,500 mg of L-carnitine L-tartrate per two capsules, or approximately 1,000 mg of L-carnitine, half the safety level observed with prolonged use. To be taken with meals, respecting the stated dose. If under treatment, pregnant, or suffering from chronic illness, consult your physician.
See L-carnitineOur fat burner comparison ranks L-carnitine among other studied active ingredients.
Frequently Asked Questions
Is L-carnitine dangerous?
At the studied doses, its tolerance is close to that of a placebo: in 17 trials, 5.4% of adverse effects under carnitine versus 5.8% under placebo. The reference assessment places the observed safety level at 2,000 mg per day with prolonged use. Precautions apply to specific situations: anticoagulants, vitamin K antagonists, thyroid treatment, valproate, dialysis, pregnancy, and cardiovascular disease.
What are the side effects of L-carnitine?
Mainly digestive disorders, nausea and diarrhea, which depend on the dose, and dry mouth. A rash was reported in one trial. At high doses, a fishy body odor is possible; it disappears upon discontinuation.
Why can L-carnitine cause a fishy odor?
Intestinal bacteria convert part of the carnitine into trimethylamine, which has a fishy odor, and the liver normally oxidizes it into odorless TMAO. When this pathway is overwhelmed by excessive intake, or is deficient, trimethylamine passes into sweat, breath, and urine. Reducing the dose or stopping makes the odor disappear.
Is L-carnitine dangerous for the heart?
It increases blood TMAO tenfold at 1,500 mg of L-carnitine L-tartrate per day, without changing inflammation markers or lipids in healthy elderly women, and TMAO returns to normal 4 months after discontinuation. In people with metabolic syndrome, a 6-month trial showed more marked progression of carotid narrowing, whereas after a heart attack, trials associate it with fewer arrhythmias and angina. In case of cardiovascular disease, the decision should be made with your cardiologist.
Is L-carnitine dangerous for the liver?
Trials suggest the opposite: in a meta-analysis of 18 trials, it lowered ALT by 8.65 IU/L and AST by 8.52 IU/L. At 3 g of L-carnitine L-tartrate per day for three weeks, no liver or kidney markers changed in healthy men.
Does L-carnitine raise blood pressure?
No. A meta-analysis of 22 trials and 1,412 adults, published in 2024, found no significant effect of L-carnitine on systolic or diastolic blood pressure.
Can you take L-carnitine while on thyroid treatment?
With your physician's approval. Carnitine slows the action of thyroid hormones in cells, to the point of having reduced symptoms of excess hormones at 2 to 4 g per day. In 60 hypothyroid patients on levothyroxine, 990 mg twice daily for 12 weeks reduced mental fatigue; TSH monitoring, determined with your physician, remains prudent.
What are the contraindications for L-carnitine?
These are mainly precautions: anticoagulants, vitamin K antagonists, with two cases of enhanced acenocoumarol effect; thyroid treatment; valproate and epilepsy; dialysis and kidney disease; cardiovascular disease; pregnancy and breastfeeding; trimethylaminuria. Only the L-form should be used, as the D,L-form has been associated with muscle weakness.
What dose of L-carnitine is safe?
Up to 2,000 mg of L-carnitine per day with prolonged use, safety is considered solid; beyond that, long-term data are lacking. 1,500 mg of L-carnitine L-tartrate provide approximately 1,000 mg of L-carnitine.
What should you know about L-carnitine safety?
That it is well tolerated at the studied doses, with digestive disorders that depend on the dose. That it increases TMAO reversibly, with no measured effect on blood pressure and with liver enzymes rather decreasing. And that medical advice is necessary when taking anticoagulants, thyroid treatment or valproate, during dialysis, during pregnancy, and in case of cardiovascular disease.
Sources
The studies cited below were identified via PubMed.
- Song X, Qu H, Yang Z, Rong J, Cai W, Zhou H. Efficacy and safety of L-carnitine in chronic heart failure: meta-analysis of randomized trials. BioMed Research International, 2017;2017:6274854. DOI
- Rubin MR, Volek JS, Gómez AL, et al. Safety measures of L-carnitine L-tartrate supplementation in healthy men. Journal of Strength and Conditioning Research, 2001;15(4):486-490. PubMed
- Johri AM, Hétu MF, Heyland DK, et al. Progression of atherosclerosis under carnitine: a randomized trial in metabolic syndrome. Nutrition and Metabolism, 2022;19(1):26. DOI
- Rocher F, Caruba C, Broly F, Lebrun C. L-carnitine treatment and fish odor syndrome: an unexpected adverse effect. Revue Neurologique, 2011;167(6-7):541-544. DOI
- Villani RG, Gannon J, Self M, Rich PA. L-carnitine combined with aerobic training does not promote weight loss in moderately obese women. International Journal of Sport Nutrition and Exercise Metabolism, 2000;10(2):199-207. DOI
- Hathcock JN, Shao A. Risk assessment of carnitine. Regulatory Toxicology and Pharmacology, 2006;46(1):23-28. DOI
- Benvenga S, Ruggeri RM, Russo A, Lapa D, Campenni A, Trimarchi F. Interest in L-carnitine, a natural peripheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism: a double-blind randomized placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism, 2001;86(8):3579-3594. DOI
- Samulak JJ, Sawicka AK, Hartmane D, et al. L-carnitine increases TMAO but not atherosclerosis markers in healthy elderly women. Annals of Nutrition and Metabolism, 2019;74(1):11-17. DOI
- Rehman HU. Fish odor syndrome. Postgraduate Medical Journal, 1999;75(886):451-452. DOI
- Koeth RA, Wang Z, Levison BS, et al. L-carnitine metabolism, a nutrient of red meat, by the gut microbiota promotes atherosclerosis. Nature Medicine, 2013;19(5):576-585. DOI
- Koeth RA, Lam-Galvez BR, Kirsop J, et al. In an omnivorous diet, L-carnitine induces an atherogenic intestinal microbial pathway in humans. Journal of Clinical Investigation, 2019;129(1):373-387. DOI
- Samulak JJ, Sawicka AK, Samborowska E, Olek RA. Plasma TMAO after L-carnitine cessation in healthy elderly women. Nutrients, 2019;11(6):1322. DOI
- DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH. L-carnitine in secondary prevention of cardiovascular disease: a systematic review and meta-analysis. Mayo Clinic Proceedings, 2013;88(6):544-551. DOI
- Anaraki SR, Aali Y, Nikbaf-Shandiz M, et al. Effects of L-carnitine on blood pressure in adults: a systematic review and dose-response meta-analysis. Clinical Therapeutics, 2024;46(2):e73-e86. DOI
- Pirmadah F, Ramezani-Jolfaie N, Mohammadi M, et al. Does L-carnitine modify liver enzymes? A systematic review and meta-analysis of randomized trials. European Journal of Nutrition, 2020;59(5):1767-1783. DOI
- Evans AM, Fornasini G. Pharmacokinetics of L-carnitine. Clinical Pharmacokinetics, 2003;42(11):941-967. DOI
- Chen Y, Abbate M, Tang L, et al. L-carnitine in adults with end-stage renal disease undergoing hemodialysis: a systematic review and meta-analysis. American Journal of Clinical Nutrition, 2014;99(2):408-422. DOI
- Perrott J, Murphy NG, Zed PJ. L-carnitine in acute valproate toxicity: a systematic review of published cases. Annals of Pharmacotherapy, 2010;44(7-8):1287-1293. DOI
- An JH, Kim YJ, Kim KJ, et al. L-carnitine versus fatigue in hypothyroid patients treated with levothyroxine: a randomized, double-blind, placebo-controlled trial. Endocrine Journal, 2016;63(10):885-895. DOI
- Martinez E, Domingo P, Roca-Cusachs A. Potentiation of acenocoumarol effect by L-carnitine. Journal of Internal Medicine, 1993;233(1):94. PubMed
- Bachmann HU, Hoffmann A. Interaction of the dietary supplement L-carnitine with the oral anticoagulant acenocoumarol. Swiss Medical Weekly, 2004;134(25-26):385. DOI
- Keller U, van der Wal C, Seliger G, Scheler C, Röpke F, Eder K. Carnitine status in pregnant women: effect of supplementation and relationship with iron status. European Journal of Clinical Nutrition, 2009;63(9):1098-1105. DOI
- Bazzato G, Coli U, Landini S, Mezzina C, Ciman M. Pseudo-myasthenic syndrome after D,L-carnitine but not after L-carnitine. The Lancet, 1981;1(8231):1209. DOI


